Collegium Pharmaceutical, Inc
- Last sale
- Nov 12, 2026 · +0.83%
- Market cap
- $776.11M
- 31.08M shares
- Filings
- 872
Q3 2026+23.6% FY25 yoy
Q3 2026−9.1% FY25 yoy
Q3 2026+5.7% FY25 yoy
Q3 2026derived+61.1% FY25 yoy
Q3 2026−7.0% FY25 yoy
Q3 2026+227.7% FY25 yoy
- $776.11M
- 20.3×
- 1.0×
- 2.6×
- 43.33%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $780,567,000 | reported | |
| FY 2024 | 2024-12-31 | $631,449,000 | reported | |
| FY 2023 | 2023-12-31 | $566,767,000 | reported | |
| FY 2022 | 2022-12-31 | $463,933,000 | reported | |
| FY 2021 | 2021-12-31 | $276,868,000 | reported | |
| FY 2020 | 2020-12-31 | $310,016,000 | reported | |
| FY 2019 | 2019-12-31 | $296,701,000 | reported | |
| FY 2018 | 2018-12-31 | $280,413,000 | reported | |
| FY 2017 | 2017-12-31 | $28,476,000 | reported | |
| FY 2016 | 2016-12-31 | $1,711,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | — | $25.10M | $25.10M | — | 31.75M sh | +0.9% | 7.7% |
| FY2024 | — | $60.03M | $60.03M | — | 31.49M sh | −1.5% | 29.5% |
| FY2023 | — | $75.00M | $75.00M | — | 31.96M sh | −6.2% | 27.3% |
| FY2022 | — | $14.06M | $14.06M | — | 34.07M sh | +2.1% | 11.5% |
| FY2021 | — | $47.86M | $47.86M | — | 33.38M sh | −4.0% | 47.1% |
Segments
Products
LineFY2025ShareChange
Belbuca$221.65M28%+4.9%
Xtampza ER$199.31M26%+4.2%
Jornay PM$148.86M19%+299.7%
Nucynta IR$115.31M15%+14.5%
Nucynta ER$80.99M10%+6.9%
Symproic and other$14.45M1.9%−4.3%
Nucynta ER———
Other———
Total$780.57M
Pharmaceutical preparations
Collegium Pharmaceutical, Inc is the 41st largest of the 554 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
ANIPANI Pharmaceuticals Inc$883.4M43.8%8.9%$1.6BHRMYHarmony Biosciences Holdings, Inc.$868.5M21.5%18.3%$2.0BTLXTelix Pharmaceuticals Ltd$803.8M55.6%0.9%—
COLLCollegium Pharmaceutical, Inc (this company)$780.6M23.6%8.1%$776.1M
CORTCorcept Therapeutics Inc$761.4M12.8%13.1%$8.1BEBSEmergent BioSolutions Inc.$742.9M28.8%7.1%$302.3MPCRXPacira BioSciences, Inc.$726.4M3.6%1.0%$1.5BAMPHAmphastar Pharmaceuticals, Inc.$719.9M1.7%13.6%$1.2BKNSAKiniksa Pharmaceuticals International, plc$677.6M60.1%8.7%$15.1BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR